Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

Multi-omics of iCPET Plasma Samples

This project aims to understand the origin of postural orthostatic tachycardia syndrome (POTS).

    • Wenzhong Xiao, PhD
    • David Systrom, MD
    • Richard Smith, PhD
    • John Jacob, PhD
    • Wei-Jun Qian, PhD

The multi-omics iCPET study of exercise intolerance has been conducted. iCPET was performed on 20 ME/CFS patients and 10 controls. Blood plasma samples were collected before, at the peak, and after the cardio-pulmonary exercise test from the arterial and the polled venous blood of each subject.

The samples were processed and analyzed in four omics analyses: (1) inflammasome (cytokine response to exercise) at NIH, (2) metabolome by Metabolon, (3) high-throughput proteomics by Pacific Northwest National Laboratories (PNNL), and (4) high-throughput proteomics by SomaLogic. The inflammasome response has been identified in these samples.

There is an exacerbated cytokine response identified in ME/CFS patients compared to controls, and the source of this enhanced response is between the pulmonary and radial arteries.

STUDY HYPOTHESIS AND DESCRIPTION

POTS is one of the more common symptoms of ME/CFS. This syndrome appears to involve the cardiopulmonary and peripheral vascular systems, both are modulated by the autonomic nervous system. It is unclear why these systems become dysfunctional to cause POTS but understanding the biological pathology underlying it will be relevant to helping understand its relationship to ME/CFS.

Cardiopulmonary exercise testing together with direct measurement through invasive arterial catheters (iCPET) has been useful to define the reason for unexplained dyspnea in general populations thought to be heart or lung in origin. Using this same diagnostic tool, ME/CFS patients have been evaluated and found to demonstrate a preload failure (PLF) pattern under maximum exercise. There are two forms of this PLF that has been observed: low flow and high flow. The low flow phenotype appears to be consistent with a failure of the autonomic nervous system to shift blood from the venous to the arterial side of the circulation or another possibility is a reduced total blood volume. On the other hand, the high flow phenotype appears as an arterial to venous shunt in the peripheral circulation or another possibility is a reduced oxygen delivery to peripheral circulatory beds or a reduced utilization by the mitochondria. 

OBJECTIVES

A blood tissue repository has been underway at the BWH for ME/CFS patients undergoing iCPET for many years and blood is available to study 84 ME/CFS patients (all with POTS) and 30 healthy participants for comparison. These blood samples are obtained before, during peak, and one hour after an iCPET procedure and will undergo analysis by proteomic, phospho-proteomic, and metabolomic methods.

Phospho-proteomics is an analysis form yet to be conducted on ME/CFS patient samples. Plasma proteomics have been conducted in ME/CFS patients but always at rest and not under stress exercise conditions when fatigue and exercise-induced differences are most likely to become evident.

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669